Every 10-Q that Imunon, Inc. (IMNN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow IMNN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMNN filings page.
Imunon, Inc. reported a continuing net loss and heightened financial risk for the six months ended June 30, 2026. The company recorded a net loss of $7.1 million, slightly higher than the $6.8 million loss a year earlier, driven by $3.8 million in research and development expenses and $3.3 million in general and administrative costs.
Liquidity remains strained. Unrestricted cash and cash equivalents were $6.9 million, with an additional $5.0 million held as restricted cash, mainly as collateral for new debt, bringing total assets to $15.0 million. Operating activities used $7.0 million of cash in the first half, while financing activities provided $10.2 million, including equity sales and a June 2026 transaction with Streeterville Capital comprising $2.5 million of Series A preferred stock and secured notes totaling $7.7 million.
The company now carries $10.8 million in total liabilities, including Notes A and B and a derivative liability related to a redemption feature on Note A. Management explicitly concludes that recurring losses, limited cash, and funding needs raise substantial doubt about Imunon’s ability to continue as a going concern, absent additional capital raises, collaborations, or other strategic transactions.
Imunon, Inc. reported a Q1 2026 net loss of $4.25M, slightly wider than the prior-year loss of $4.10M, as operating expenses rose to $4.31M driven mainly by higher research and development spending.
Cash and cash equivalents declined to $4.79M at March 31, 2026 from $8.78M at year-end, with $3.99M used in operating activities in the quarter. Management concludes there is substantial doubt about Imunon’s ability to continue as a going concern without new capital.
The company remains a clinical-stage biotech focused on its DNA-based immunotherapy IMNN-001 for advanced ovarian cancer. Final Phase 2 OVATION 2 data showed a 14.7‑month improvement in median overall survival versus standard chemotherapy alone, and a 24.2‑month gain in patients also receiving PARP inhibitors, supporting advancement into a Phase 3 pivotal trial.
Imunon, Inc. reported Q3 2025 results and operational updates. The company posted a net loss of $3.43 million for the quarter and $10.27 million for the nine months ended September 30, 2025. Operating expenses fell to $3.48 million in Q3 (from $4.96 million a year ago) and to $10.39 million for the nine-month period (from $14.99 million), driven by lower research and development spending.
Cash and cash equivalents were $5.25 million as of September 30, 2025. Year to date, Imunon used $10.24 million in operating cash flows and raised $9.89 million via equity financings and warrant exercises. Management disclosed substantial doubt about the company’s ability to continue as a going concern. As of November 10, 2025, shares outstanding were 3,070,354.
The company effected a 15‑for‑1 reverse stock split on July 25, 2025, increased authorized common shares to 350,000,000 on July 11, and issued a 15% stock dividend on August 21. Clinically, positive Phase 2 OVATION 2 data support IMNN‑001 in advanced ovarian cancer, and the Phase 3 OVATION 3 trial began enrolling in July 2025 with four sites open as of quarter end.